Tirzepatide: Three new post hoc analyzes support efficacy in type 2 diabetes

Berlin – Tirzepatide reduces HbA1c and body weight compared to placebo or semaglutide, regardless of basal beta-cell function. This emerges from a post-hoc analysis of the SURPASS 1 and 2 studies by Thomas Forst, CRS